Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Chimeric antigen receptor-T-cellebehandling

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Androgent insensitivitetssyndrom opdaget pga. diskordans mellem prænatale vurderinger af fosterkøn.

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Behandling af tymom og thymuskarcinom

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Bilateral caput femoris-epifysiolyse efter epileptisk anfald

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Osmotisk demyeliniseringssyndrom

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Uafklaret dyspnø.

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Low incidence of hemorrhagic cystitis following ex vivo T-cell depleted haploidentical hematopoietic cell transplantation in children

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Tumor necrosis factor induces rapid down-regulation of TXNIP in human T cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

Although treatment of haematological cancer has improved significantly during the latest decades, the prognosis is poor in case of relapse or refractory disease. This review describes the chimeric antigen receptor (CAR) T-cell therapy, which has emerged as a new promising treatment principle, in which the patient's own T-cells are genetically modified to recognise cancer cells. The possible side effects are usually only transient. A commercial CD19 CAR T-cell product has recently been approved as treatment for acute lympho-blastic leukaemia in children and young adults in Denmark, and a non-commercial CAR T-cell production is being established.

Original languageEnglish
JournalUgeskrift for Laeger
Volume181
Issue number20A
ISSN0041-5782
Publication statusPublished - 14 Oct 2019

ID: 58521171